Patients with acromegaly might not be at higher risk for dopamine agonist- induced impulse control disorders than those with prolactinomas


ÖZKAYA H. M., Sahin S., Korkmaz O. P., DURCAN E., Sahin H. R., ÇELİK E., ...More

GROWTH HORMONE & IGF RESEARCH, vol.55, 2020 (SCI-Expanded) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 55
  • Publication Date: 2020
  • Doi Number: 10.1016/j.ghir.2020.101356
  • Journal Name: GROWTH HORMONE & IGF RESEARCH
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus, BIOSIS, EMBASE, MEDLINE
  • Keywords: Acromegaly, Dopamine agonist, Impulse control disorder, Prevalence, NONFUNCTIONING PITUITARY-ADENOMAS, COMPULSIVE BEHAVIORS, PARKINSONS-DISEASE, SHORT-FORM, AGE, HYPERPROLACTINEMIA, ASSOCIATION, PERSONALITY, CABERGOLINE, THERAPY
  • Istanbul University Affiliated: Yes

Abstract

Objective: To evaluate the prevalence of impulse control disorders (ICD) and psychiatric symptoms in patients with acromegaly receiving dopamine agonists (DA) in comparison with those with prolactinoma, nonfunctioning pituitary adenomas (NFA), and healthy controls (HC).